BioDome Partners Announces Exclusive Option Deal with Children's Hospital Los Angeles

BioDome Partners and Children’s Hospital Los Angeles have entered into an exclusive option agreement focusing on the development of potential treatments for inflammatory bowel disease (Crohn's & ulcerative colitis) and necrotizing enterocolitis.

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
NRG4-induced epithelial cell survival represents a powerful endogenous mechanism for restraining inflammation-induced intestinal damage, which we hypothesize can be harnessed therapeutically.

San Francisco, CA (PRWEB) June 23, 2014

BioDome Partners, LLC and Children’s Hospital Los Angeles (CHLA) announced today that they have entered into an option agreement under which BioDome Partners has the exclusive right to secure an exclusive license for technology and IP of CHLA pertaining to the use of neuregulin-4 (NRG-4) for the treatment of inflammatory bowel disease (IBD) and necrotizing enterocolitis (NEC).

“This option agreement with CHLA is an example of our focus and dedication to identify and mobilize potential game changing therapies to serve patients in need,” said Artin Asadourian, Managing Partner of BioDome Partners. “We are pleased to continue to collaborate with CHLA on the development of NRG-4 through this mutually beneficial agreement which provides BioDome Partners the exclusive rights to license NRG-4 in the near future.”

Added Dr. David Maggs, Managing Partner, BioDome Partners, “The pre-clinical NRG-4 results in both IBD and NEC models are impressive, and demonstrate a real potential to change the way these diseases may be treated in the future.”

“We are delighted to be working with BioDome Partners on this opportunity to open a new potential therapeutic avenue for necrotizing enterocolitis and other intestinal disorders,” said Mark Frey, PhD, Assistant Professor of Pediatrics and Biochemistry and Molecular Biology at the Saban Research Institute at Children's Hospital Los Angeles. “NRG4-induced epithelial cell survival represents a powerful endogenous mechanism for restraining inflammation-induced intestinal damage, which we hypothesize can be harnessed therapeutically.”

“As CHLA continues to grow its translational assets and capabilities, this collaboration with the BioDome team solidifies our goal of effectively translating our research to the clinic with an ideal set of partners, and we look forward to a fruitful collaboration,” added Jessica Rousset, director, CHLA Center for Innovation.

About BioDome Partners
BioDome Partners, LLC, headquartered in San Francisco CA, is a privately held biotech incubator partnering with leading research institutions and inventors to catalyze innovative new business ventures. BioDome Partners focuses on identifying novel break through therapies that can help serve markets with significant unmet needs.

For more information, visit http://www.biodomepartners.com. Follow us on Twitter @biodomepartners.

About Children’s Hospital Los Angeles
Children's Hospital Los Angeles has been named the best children’s hospital on the West Coast and among the top five in the nation for clinical excellence with its selection to the prestigious U.S. News & World Report Honor Roll. Children’s Hospital is home to The Saban Research Institute, one of the largest and most productive pediatric research facilities in the United States. Children’s Hospital is also one of America's premier teaching hospitals through its affiliation since 1932 with the Keck School of Medicine of the University of Southern California.

For more information, visit http://www.CHLA.org. Follow us on our blog http://www.researchlablog.org.


Contact